bluuebunny/crossref_metadata_2025_split huggingface dataset:
Therapeutic implications and sites of relapse predicted by elevated posttherapy erythrocyte sedimentation rate in early stage Hodgkin disease
Authors: Friedman Samuel , Henry‐Amar Michel , Cosset Jean‐Marc , Carde Patrice , Hayat Marcel , Dupouy Noelle , Tubiana Maurice 
Published: February 2007

AbstractAn analysis was performed of all 57 early relapses (ER) (within 18 months of therapy initiation) seen in a group of 301 patients treated on three successive European Organization for Research and Treatment of Cancer (EORTC) protocols from 1964 to 1981; to determine whether a posttherapy elevated erythrocyte sedimentation rate (ESR) (⩾30mm) could predict the type of relapse and the effect upon the relapse of different therapies received. Overall most ER occurred in extranodal (EN) (42%) or irradiated transdiaphragmatic nodal (TDN) (40%) sites. Compared to patients with normal posttherapy ESR (n = 12), patients with elevated posttherapy ESR (n = 45) had the same proportions of outfield and late relapses; more frequent multiple sites of ER (38% vs. 25%), increased proportions of early EN relapses (16% vs. 3%), TDN relapses (17% vs. 2%), and other ER (6% vs. 1%). ER were most frequently observed between 1964 and 1971, and “modern” radiotherapy (Rt) decreased ER overall from 27% to 13% and for elevated posttherapy ESR patients from 54% to 25%. When chemotherapy (Ct) was used as either adjuvant or initial therapy, ER were greatly reduced vs. Rt alone [overall (6% vs. 28%) and for patients with elevated posttherapy ESR (10% vs. 39%)]. Stepwise logistic regression showed Ct to be the most important factor “protecting” from EN relapse, but elevated posttherapy ESR was still significant. For early TDN relapse, elevated posttherapy ESR had the highest predictive value for relapse, greater than the types of radiation fields used and chemotherapy. An unexplained elevated posttherapy ESR, regardless of previous therapy, predicts for ER from aggressive HD, frequently in EN and irradiated areas, and warrants further early therapy.
Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura
Authors: Semple John W. , Bruce Suzanne , Freedman John 
Published: February 2007

AbstractNatural killer (NK) cell activity was studied in 17 patients with primary chronic idiopathic autoimmune thrombocytopenic purpura (ATP). Fifteen of 17 patients had a significantly reduced NK cytotoxicity against 51chromium labeled K562 target cells (mean LU20% = 18 ± 20 in patients versus 65 = 2 5 in controls, P < 0.001). NK activity was also significantly reduced in all of six patients with secondary ATP as compared with normal controls (LU20%28±15, respectively, P < 0.005). The NK activity in both patient groups correlated with the duration of therapy being received (r = 0.60, P < 0.001). Immunophenotypic analysis of peripheral blood mononuclear cells from patients with ATP revealed that CD8‐ cells bearing CD57 (HNK‐1, Leu 7) and CD3‐ cells bearing CD56 (Leu 19) were quantitatively within the normal range. These findings indicate that patients with ATP have a functional defect in NK cytolytic activity.
Granulocyte‐macrophage colony stimulating factor for the treatment of drug induced agranulocytosis
Authors: Nand Sucha , Bayer Robert , Prim Richard A. , Felten William , Godwin John E. 
Published: February 2007

AbstractDrug induced agranulocytosis is an uncommon but potentially fatal complication. In some cases, it may be associated with hypoplasia and depletion of granulocytic precursors in the marrow, leading to prolonged neutropenia. We report on the use of granulocytic‐macrophage colony stimulating factor (GM‐CSF) in two such cases, at a dose of 10 μg per kilogram per day subcutaneously. The absolute neutrophil count rose above 500/mm3 in 3 days in both cases. We believe that GM‐CSF expedited the recovery of granulocyte counts in our patients and warrants further study in the management of drug induced neutropenia.
Usefulness of electron microscopy in the diagnosis of congenital dyserythropoietic anemia type I: Report of a case
Authors: Facon T. , Zandecki M. , Caulier M. T. , Mannessier L. , Fenaux P. , Jouet J. P. , Bauters F. 
Published: February 2007

AbstractThis report describes a case of congenital dyserythropoietic anemia (CDA) type I diagnosed in a 22‐year‐old woman with a two year history of macrocytic anemia. Light microscopy study of bone marrow disclosed only minor and nonspecific findings, without erythroid hyperplasia. Electron microscopy of bone marrow erythroblasts surprisingly showed most of the classical features of CDA type I. Electron microscopy may be an important tool for the diagnosis of macrocytic anemia of obscure origin, especially in young patients.
CD7 false‐positive acute myelogenous leukemia and promyelocytic leukemia cell line HL‐60: Characterization of CD7 epitopes by four monoclonal antibodies
Authors: Imamura Nobutaka , Ota Hiromi , Kuramoto Atsushi 
Published: February 2007

AbstractPhenotypes of cells from 12 patients with acute myelogenous leukemia (AML) were analysed by means of a fluorescence‐activated cell sorter utilizing a panel of monoclonal antibodies (MAbs). A majority of the cells from peripheral blood coexpressed the antigens against MAbs CD11, CD13, and CD33 but did not express the antigens against CD1, CD3, CD4, CD5, CDB, CD19, CD20, CD21, CD41 and 42, and glycophorin A. Three out of the 12 cases expressed CD7 antigen. However, one of them showed no reaction with Tp40 MAb, whereas the others showed reaction with Leu9 and T55. The discrepancy of reactivities between Leu9 and Tp40 MAbs prompted us to study the promyelocytic leukemia cell line HL‐60, which showed similar reactions against Leu9 and Tp40 MAbs. Leu9, OKT16, and T55 MAbs reacted strongly with HL60 cells, whereas Tp40 MAb, which reacted strongly with T‐cell leukemia cell line Jurkat, showed no reaction.The reactivity of Leu9, OKT16, and T55 MAbs with HL‐60 cells was completely inhibited after preincubation with aggregated human immunoglobulin G (AHIG), which clearly shows the existence of nonspecific binding between these 3 MAbs and HL‐60 cells via FcγR.On the basis of our experiments, we conclude that HL‐60 cells bind nonspecifically with Leu9, OKT16, and T55 MAbs via FcRI, and this is suggestive that de novo AML cells probably behave in the same fashion. Hence, we recommend that the utilization of murine IgG2a and IgG3 MAbs should be avoided especially in cell surface analysis of myeloid leukemic cells.
Occupational risk for hematological malignancies
Authors: Pasqualetti Paolo , Casale Raffaele , Colantonio Domenico , Collacciani Antonio 
Published: February 2007

AbstractA case‐control study was conducted in 620 cases of hematological malignancies and in 1,240 age‐ and sex‐matched controls in order to verify the possible association between occupation, toxic substances exposure, and the risk of hematological neoplasias. The results demonstrate that farmers and industrial workers have a significant risk for hematological malignancies. Exposure to asbestos, aromatic hydrocarbons, fertilizers, mineral oils, pesticides, and radiations is associated with a significant increase in the risk for these malignant diseases. These data are in agreement with previously reported data, and require a confirmation in larger, prospective studies.
Hemoglobin redondo [β 92(F8) His → Asn]: An unstable hemoglobin variant associated with heme loss which occurs in two forms
Authors: Wajcman H. , Vasseur C. , Poyart C. , Blouquit Y. , Galacteros F. , Santo D. Esperito , Peres M. J. , Martins M. C. 
Published: February 2007

AbstractHb Redondo [β92(F8) His→Asn] illustrates how post‐translational structural modifications may modify the phenotypic expression of an unstable hemoglobin. This variant was found in a Portuguese patient suffering from a chronic hemolytic anemia. The electrophoretic pattern demonstrated that it occurred in two forms, both being semi‐hemoglobins: the fastest one migrating like HbS and the other like HbA2; after a few days of storage at 4°C the intensity of the slowest Hb fraction decreased while that of the other increased proportionally. In both cases, the RP‐HPLC analysis of the tryptic digest of the aminoethylated β chains demonstrated the presence of an abnormal βT10 peptide carrying a His→Asx substitution. Microsequence study of these two peptides demonstrated that the slowest abnormal Hb fraction had a β92 His → Asn substitution and the fastest a His → Asp at the same site.All these results suggest that the β92 His → Asn variant loses readily its heme group and that a deamidation occurs rapidly in vitro, yielding a β92 Asp semi‐hemoglobin. The oxygen affinity of the patient's red blood cells was increased, leading to a stimulation of erythropoiesis and to a macrocytic hemolytic disease.
Induction of carbonic anhydrase I isozyme precedes the globin synthesis during erythropoiesis in K562 cells
Authors: Kondo Takahito , Isobe Hiroshi , Kawakami Yoshikazu , Sakai Masaharu , Nishi Shinzou , Taniguchi Naoyuki 
Published: February 2007

AbstractInduction of carbonic anhydrase isozyme I (CA‐I) by erythropoietin or hemin was investigated using erythroleukemia (K562) cells. Immunological estimation and purification of carbonic anhydrases showed that untreated K562 cells contained only carbonic anhydrase isozyme II(CA‐II), while incubation of the cells with 2 units of erythropoietin (EP) per ml of the incubation medium or with 50 μM hemin resulted in the induction of CA‐I. The purified CA‐I induced in K562 cells was enzymatically and immunologically identical to that from mature erythrocytes. Flow cytometric analysis showed that incubation of K562 cells with EP as well as hemin induced CA‐I at the 3rd h, while α‐globin was detected at the 8th h. Northern blot analysis of CA‐I mRNA using a cloned genomic DNA as a probe showed that mRNA of CA‐I was induced by EP. These results suggest that induction of CA‐I is regulated at the transcriptional level during developmental changes of erythroid cells, and that CA‐I may play a physiologically important role during erythroid differentiation.
Pelger—Huet anomaly in an infant with multiple congenital anomalies
Authors: Fishbein Julie D. , Falletta John M. 
Published: February 2007

AbstractWe report a new case of Pelger‐Huet anomaly (PHA) evident from the first day of life in an infant with multiple congenital anomalies suggestive of Fryn syndrome. The infant's parents are not affected by PHA, raising the possibility that the PHA resulted from a spontaneous mutation.
Concurrent acute myeloid leukemia and systemic mastocytosis
Authors: Wong K. F. , Chan J. K. C. , Chow T. C. , Chan J. C. W. , Ma S. K. , Kwong Y. L. 
Published: February 2007

AbstractA 51‐year‐old woman presented with concurrent systemic mastocytosis and acute myeloid leukemia associated with a clonal karyotypic anomaly of t(8;21). Cytochemical, histologic, and cytogenetic studies helped in the distinction from a recently described entity: acute myeloid leukemia with marrow basophilia. Although the leukemia responded well to aggressive chemotherapy, the mastocytosis component worsened, illustrating the inherent resistance of mastocytosis to chemotherapy.
Cardiac complications observed in elderly patients following 2′‐deoxycoformycin therapy
Authors: Grem Jean L. , King Susan A. , Chun Hoo G. , Grever Michael R. 
Published: February 2007

AbstractDeoxycoformycin (dCF) is an investigational nucleoside with significant activity in hairy cell leukemia, cutaneous T‐cell lymphoma, and chronic lymphocytic leukemia. During a 4‐year period, 11 patients have experienced cardiac events as a complication of dCF therapy under NCI sponsorship. The cases are presented and recommendations for the administration of dCF to patients with pre‐existing heart disease are made.
Simple method for differentiating between HLA and platelet‐specific antibodies by flow cytometry
Authors: Freedman J. , Hornstein A. 
Published: February 2007

AbstractSince platelets express both platelet‐specific and class I HLA antigens, serum antiplatelet reactivity assessed by most platelet antibody techniques could be due to antibodies with either or both specificities. Flow cytometric analysis of sera for detection of anti platelet antibody commonly employs a purified platelet preparation as target cells. A method is described for investigating sera for platelet antibodies by flow cytometry using a mixture of platelets and lymphocytes. The mixture of lymphocytes and platelets as target cells has the advantage of confirming the presence of the HLA antibodies in reactive sera. The concomitant use of platelets and lymphocytes treated with citric acid, pH3, or with chloroquine (to remove or alter surface HLA antigens without affecting platelet specific antigens) may further assist in identifying antiplatelet antibodies in alloimmunized patients. These techniques may also be useful in platelet crossmatching procedures.
Hemophagocytic syndrome associated with aggressive natural killer cell leukemia
Authors: Okuda Tsukasa , Sakamoto Shinichi , Deguchi Takeshi , Misawa Shinichi , Kashima Kei , Yoshihara Takao , Ikushima Satoshi , Hibi Shigeyoshi , Imashuku Shinsaku 
Published: February 2007

AbstractWe describe a patient who had aggressive natural killer cell leukemia with profound hemophagocytosis. This combination must be underscored as one of several hemophagocytic syndromes. Activated phagocytes in the bone marrow appeared morphologically normal and could possibly be proliferating in response to some cytokine(s) such as interferon‐gamma produced by leukemic cells, whose serum level was found to be extremely elevated in this case.
Aplastic anemia associated with systemic lupus erythematosus
Authors: Sumimoto Shin‐Ichi , Kawai Masahiko , Kasajima Yoshiki , Hamamoto Torata 
Published: February 2007

AbstractHematologic complications of systemic lupus erythematosus (SLE) usually involve peripheral destruction of blood cells. We report a case of aplastic anemia associated with SLE observed during the remission phase of SLE 3 months after the beginning of treatment. CD8+ T cells in the patient's bone marrow may have suppressed maturation of hematopoietic progenitor cells, which may have induced the aplastic anemia associated with SLE. Repeated therapy with high‐dose methylprednisolone resulted in lasting remission.
Detection of minimal residual disease in acute lymphoblastic leukemia by flow cytometry with monoclonal antibodies
Authors: Imamura Nobutaka , Kuramoto Atsushi 
Published: February 2007

AbstractTo detect more precisely the minimal residual disease in acute lymphoblastic leukemia (ALL), two‐color flow cytometric analysis for the detection of cell‐surface antigen (CD10; CALLA) and nuclear terminal deoxynucleotidyl transferase (TdT) was performed in the six patients with CALLA‐positive ALL coexpressing TdT. In all patients, the leukemic blasts coexpressed la (HLA‐DR), CD9, CD19, CD20, CD24, and CD10. Five of six patients achieved complete remission, but one has so far relapsed. No leukemic blasts (CD10+, TdT+) were detected at the time of complete remission. During maintenance chemotherapy, leukemic blasts coexpressed C10 and TdT were found 2.32% in the patient's peripheral blood by two‐color analysis, whereas no obvious leukemic cells were recognized morphologically. The patient relapsed leukemia with the same phenotype 4 weeks after the examination. On the basis of our findings, we suggest that two‐color flow cytometric analysis with the use of these antibodies is quite valuable to detect the minimal residual leukemic cells in a patient with ALL. The reduction of leukemic cells below the threshold of detection of methods currently available appears to be necessary to achieve a cure in ALL. Hence accurate diagnosis of ALLs with monoclonal antibodies (MAbs) should contribute substantially to the development of an effective form of therapy for their cure.
HLA antibodies—the cause of platelet alloimmunization in chinese
Authors: Chow Mo‐Ping , Yung Chien‐Hui , Hu Hui‐Yu , Tzeng Jaw‐Lin , Lin Jeong‐Shi , Lin Wen‐Mei , Lin Chung‐King 
Published: February 2007

AbstractLymphocytotoxicity test (LCT) and platelet suspension immunofluorescence test (PSIFT) were used together to screen platelet‐associated antibodies in patients who received long‐term platelet transfusion. Twenty‐four of 53 patients (45.3%) were immunized subsequently. Since the concordence of LCT and PSIFT was 100%, most of the platelet associated antibodies were of HLA specificity, and platelet specific antibody alone (in absence of HLA) was not detected. The identified antibodies were anti‐A2, A11, A24, B5, B46, B57, B60, and B62. The majority of them were against the high frequency HLA antigens in the Chinese population. The development of antibody could not be correlated with the number of platelet‐donors exposed, the time interval after the initiation of platelet transfusion, or the percentage of reactive lymphocytotoxic panels. HLA antibody was the major factor in causing platelet alloimmunization in the Chinese patients. However, some other unknown factors should be looked for. In addition, ABO incompatibility did not affect the posttransfusional increment while the platelet was compatible with LCT crossmatching.
Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation
Authors: Wada Hideo , Ohiwa Michiaki , Kaneko Toshihiro , Tamaki Shigehisa , Tanigawa Motoaki , Shirakawa Shigeru , Koyama Masato , Hayashi Tatsuya , Suzuki Koji 
Published: February 2007

AbstractPlasma thrombomodulin (TM) levels were significantly elevated at disease onset in patients with thrombotic thrombocytopenic purpura (TTP) and disseminated intravascular coagulation (DIC), but was not in those with essential thrombocythemia and idiopathic thrombocytopenic purpura. However, in patients with TTP and DIC, TM levels decreased significantly after they achieved complete remission. In both TTP and DIC patients, plasma TM levels at onset in those with poor prognosis were higher than that in those with good prognosis. Among DIC patients, the plasma TM level was higher in those with organ failure than in those without, but there were no differences among patients with various underlying diseases associated with DIC. It is speculated that the plasma TM level reflects damage to vascular endothelial cells or organ failure and that it is useful in assessing prognosis for patients with DIC and TTP.
Expression of high affinity binding sites for erythropoietin on L8057 cells, a mouse megakaryoblastic cell line, associated with cell differentiation
Authors: Yoshida Takeshi , Ishida Yoji , Sasaki Hideki , Inoue Tohru , Kaku Kohei , Kaneko Toshio 
Published: February 2007

AbstractIn this study, specific binding sites were examined for erythropoietin (EPO) on the mouse leukemic cell line, L8057. This cell line is megakaryoblastic in origin as evidenced by an enlargement of cell size, multinuclearity, intense activity of acetylcholinesterase, more expression of glycoprotein Ilb and IIIa antigen, and higher ploidy distribution after the treatment with 12‐o‐tetradecanoylphorbor‐13‐acetate (TPA). The original undifferentiated cells possessed a single class of low affinity binding sites for recombinant human (rh) EPO with a Kd of 3.5 nM. Following the treatment with TPA, high affinity binding sites (Kd; 440 pM) were expressed in addition to the low affinity sites. EPO stimulated the incorporation of 3H‐leucine into TPA‐treated L8057 cells, and the maximal effect of EPO was observed at the same order as the Kd value of high affinity sites.The present data demonstrates that the expression of high affinity binding sites for EPO is associated with the differentiation of L8057 cells which have megakaryocytic characteristics. Furthermore, protein synthesis stimulated by EPO may be mediated through the high affinity sites.
CD45RA expression by CD4 T lymphocytes in tumors invaded by B‐cell non‐Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD)
Authors: Jacob Marie‐Christine , Favre Mireille , Lemarc'Hadour FrançOis , Sotto Marie‐France , Bonnefoix Thierry , Sotto Jean‐Jacques , Bensa Jean‐Claude 
Published: February 2007

AbstractLittle is known about the role of tumor infiltrating T lymphocytes (TIL‐T) in the pathogenesis of malignant diseases and collaboration between normal and malignant cells has not yet been proved.In the present work, we have investigated whether immune T lymphocytes exist in tumors invaded by B‐cell non‐Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). Therefore, we have studied the reactivity of the CD45RA monoclonal antibody, which discriminates between naive and memory CD4 T lymphocytes. Our results showed far lower percentages of CD4+ CD45RA+ in malignant lymphoma (30.3 ± 15.0% in B‐cell NHL, and 37.4 ± 18.6% in HD) than in reactive hyperplasia (54.7 ± 13.2%), leading to the conclusion of an accumulation of immune cells in tumor microenvironment.A further heterogeneity in the relative proportion of naive and memory TIL‐T was also observed within lymphoma (range: 11 to 68% in B‐cell NHL, 5 to 69% in HD). In B‐cell NHL, it was related to histological features, as documented by the Kiel classification (P = .028), and to a stronger extent to cytological characteristics analysed with the Grenoble classification (P < .0001): class 1 NHL, which are essentially indolent NHL displayed lower naive cells (22.2 ± 7.4%) than class 3 NHL, which are more aggressive (40.1 ± 16.1%). Among the monoclonal antibodies (mAb) defining the B‐cell clone phenotype or activation state (CD19, CD20, CD21, CD22, CD23, CD24, CD5, CD10, CD11a, and Ki67), only CD23 (P = .0003) and Ki67 (p = .0007) revealed statistical association with the percentage of naive CD4 lymphocytes. No correlation could be demonstrated with the proportion of whole TIL‐T, activated CD3 DR TIL‐T, or CD4 subset.
Desmopressin (d‐DAVP) effects on platelet rheology and von willebrand factor activities in uremia
Authors: Zeigler Zella R. , Megaludis Alexis , Fraley Donald S. 
Published: February 2007

AbstractBleeding times, von Willebrand activities, and platelet retentions were examined before and following d‐DAVP in 13 uremic patients. Shortening of the bleeding time from 16.6 ± 2.2 (SEM) to 6.8 ± 0.7 min was seen in six patients. However, bleeding times remained ± 20 min in the remaining seven individuals. The only baseline parameter that correlated with response to d‐DAVP was the amount of blood loss (mg/min) during the bleeding time test. Responders had normal blood loss values averaging 6.2 ± 1.5 mg/min. By contrast, these values were elevated in 6/7 of the non‐responders and averaged 28.4 ± 5.9 mg/min (P = 0.01). Von Willebrand activities increased following d‐DAVP in the responders but not in the non‐responders. Platelet retention was uniformly low in all patients and improved from 21.0 ± 7.0% to 75.0 ± 7.9% (P = <0.001) following d‐DAVP in responders but not non‐responders. To further define the retention abnormality in uremia, the two‐stage platelet retention assay was performed prior to d‐DAVP. Most of the patients (9/12) had both first‐ and second‐phase abnormalities. Therefore, the retention defect in uremia appears to be more complex than that seen in von Willebrand's disease (2nd phase abnormality only). Nevertheless, d‐DAVP seems to improve platelet rheology in uremic individuals whose von Willebrand activities increase with d‐DAVP.